ArticlePathogens (Basel, Switzerland)2024
Prodigiosin as an Antibiofilm Agent against the Bacterial Biofilm-Associated Infection of
Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- Microbial pigments as multi-functional cosmeceuticals: mechanism of action and sustainable production.Archives of microbiology · 2026Review
- Isoliquiritigenin targets las, rhl, and Pqs quorum sensing systems to mitigate the virulence and infection of Pseudomonas aeruginosa.BMC microbiology · 2025Article
- Identification and characterization of alternative homologs of histidinol-phosphate phosphatase in Pseudomonas aeruginosa.BMC microbiology · 2025Article
- Application of microbial pigments in the pharmaceutical industry: current status and opportunities.Archives of microbiology · 2025Review
- Integrated Biological and Chemical Investigation of Indonesian Marine Organisms Targeting Anti-Quorum-Sensing, Anti-Biofilm, Anti-Biofouling, and Anti-Biocorrosion Activities.Molecules (Basel, Switzerland) · 2025Article
- Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications.Frontiers in microbiology · 2025Review
- The Potential of Phage Treatment to Inactivate Planktonic and Biofilm-FormingMicroorganisms · 2024Article
- Prodigiosin: unveiling the crimson wonder - a comprehensive journey from diverse bioactivity to synthesis and yield enhancement.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.